A daily HIV pill has been the routine for millions since 2012.
That routine might just become… weekly.
Gilead Sciences and Merck just dropped positive Phase 3 results for a combined pill — one tablet, once a week, matching daily treatment at keeping HIV suppressed.
Here's the story behind that headline.
Two trials. Same story.
Islend-1 enrolled 607 people already stable on Gilead's daily Biktarvy.
They switched to the weekly combo — lenacapavir + islatravir, nicknamed ISL/LEN.
At week 48?
Islend-2 tested it against a broader mix of daily regimens in 626 people.
Same result. Virological failure rates barely moved between weekly and daily.
One pill a week, doing what one pill a day used to do.
This isn't islatravir's first rodeo.
Back in 2021, the FDA hit some of Merck's islatravir trials with a clinical hold — high doses were quietly tanking patients' lymphocyte and CD4 counts.
That's the immune system's foot soldiers. Not something you mess with lightly.
So every eye at this readout was on one number.
And the data came back clean — no meaningful difference in lymphocyte counts between arms at week 48.
The ghost got exorcised.
Gilead's own clinical development lead in virology said it plainly: adherence is still one of the biggest fights in HIV care.
Miss doses, and suppression slips.
Cut daily to weekly, and that math changes fast.
👉 For the millions managing HIV as a chronic, lifelong condition, fewer pill-popping days can mean real, sustained control.
This pill would land in a market that already has GSK's Cabenuva — a long-acting injectable dosed monthly or bimonthly.
Some patients want out of daily pills entirely and are fine with a jab.
Others are needle-shy and want the pill format, just less often.
Gilead's not stopping at weekly either — its Daybreak programme is already chasing six-month dosing with antibody combinations.
The data goes to the International AIDS Conference in Rio next.
The direction of HIV treatment, though, already feels obvious: less frequent, less friction, more lives back on track.
Sources:
That's all for now!
